MHRA Proposes New Regulatory Pathway for Rare Disease Therapies
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on a new, technology‑agnostic regulatory pathway for rare disease therapies. Central to the proposal is an Investigational Marketing Authorisation (IMA) that merges clinical trial approval with a progressive route to marketing authorisation, allowing rolling data submissions and modular assessments. The framework encourages adaptive trial designs, real‑world evidence, surrogate endpoints and digital‑twin modelling to overcome scientific and commercial barriers. The consultation runs until 30 July and seeks input from pharma, biotech, clinicians, patients and other stakeholders.
FDA’s Megha Kaushal ASGCT Talk: PFDD, Patient Voices, Decision-Making
At the 2026 ASGCT meeting, FDA Acting Deputy Director Megha Kaushal highlighted the agency’s Patient‑Focused Drug Development (PFDD) initiative, urging early integration of patient and caregiver input into cell and gene therapy trials. She emphasized that families’ lived‑experience data should inform...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced FDA approval of Guardant360® Liquid CDx, the largest liquid‑biopsy panel on the market, featuring a 100‑fold expanded genomic footprint. The test merges genomic and epigenomic profiling from a single blood draw, delivering several‑fold higher circulating tumor DNA...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
IntraBio announced regulatory authorization to launch its pivotal Phase III trial of levacetylleucine (AQNEURSA) in CACNA1A‑related disorders across the United States, United Kingdom, European Union and Switzerland. The 12‑week, randomized, double‑blind, placebo‑controlled crossover study will be conducted at twelve multinational sites...
Airway Therapeutics CEO on Rethinking Bronchopulmonary Dysplasia Trials
Airway Therapeutics is advancing zelpultide alfa, an investigational biologic aimed at preventing bronchopulmonary dysplasia (BPD) in extremely preterm infants born between 22 and 27 weeks gestation. CEO Marc Salzberg highlighted the clinical and operational hurdles of neonatal trials, including limited...
Canagliflozin - Another Top Longevity Drug
A small, exploratory randomized trial tested dapagliflozin, an SGLT2 inhibitor, in early‑stage Alzheimer’s disease. The primary endpoint—magnetic resonance spectroscopy measurement of brain N‑acetylaspartate—showed no significant difference versus placebo. Nonetheless, the drug markedly increased systemic glucose disposal, confirming its expected metabolic...
Reimagining Vaccine Development with AI
Traditional vaccine trials can take 5‑10 years, limiting response to emerging pathogens. AI‑driven adaptive designs and predictive analytics promise to shorten timelines, achieving 85‑90% outcome prediction accuracy versus 70‑75% for conventional models. By automating site selection, forecasting disease hotspots, and...
Peer-Reviewed Paper Says Genetically Engineering Ticks to Spread Meat Allergies Is “Morally Obligatory"
A peer‑reviewed paper argues that genetically editing lone‑star ticks to spread alpha‑gal syndrome—a meat allergy—constitutes a moral bio‑enhancement. The authors claim the ticks could be engineered to carry the allergy, survive longer, and avoid other diseases, making meat consumption less...
Cyclana Bio Granted Health Research Authority Approval
Cyclana Bio secured Health Research Authority and Research Ethics Committee approval for its 500‑patient observational study, PEMP, targeting endometriosis. The first participants have been enrolled at Peterborough City Hospital and the Rosie Hospital in Cambridge. Funded by a $6.3 million pre‑seed...
What It Takes to Run Rare Pediatric Disease Trials Across Borders: Insights From Polaryx Therapeutics
Polaryx Therapeutics is gearing up to test its oral candidate PLX-200 in a Phase II SOTERIA basket trial for four ultra‑rare lysosomal storage disorders—CLN2, CLN3, Krabbe and Sandhoff. The FDA has granted Fast Track designation for all four indications, promising closer...
Developing a Drug To Reverse Heart Disease
Repair Biotechnologies’ lead candidate, REP-0004, is an mRNA‑based lipid nanoparticle designed to deliver a cholesterol‑degrading protein exclusively to hepatocytes. The FDA granted the drug orphan‑drug status and the company targets a Phase 1 start by mid‑2027, pending GMP manufacturing and IND‑enabling...
Adenine Base Editing Demonstrates Profound Impact on Rare Disease
Researchers at The Jackson Laboratory used adenine base editing to repair the SCN1A R613X mutation that causes Dravet syndrome in mice. A single brain injection corrected roughly 60% of the defective DNA, restoring normal gene expression and dramatically reducing seizures....
What Psychedelic Clinical Trials Could Teach Psychiatry
Treatment‑resistant depression (TRD) affects roughly one‑third of U.S. adults on antidepressants and remains a high‑need, low‑treatment area. Compass Pathways’ synthetic psilocybin, COMP360, recently achieved its primary endpoints in two Phase III trials—258 patients in COMP005 and 581 in COMP006—showing rapid, durable...
Ivermectin for Hantavirus: Real Science or Wishful Thinking?
The blog post debunks circulating claims that ivermectin treats hantavirus, noting that no clinical trials or direct studies exist to support such use. It explains that while ivermectin has demonstrated in‑vitro antiviral activity against several RNA viruses, hantavirus has not...
Dr. Reddy’s Laboratories Launches Its Generic Semaglutide Injection in Canada
Dr. Reddy’s Laboratories received Health Canada’s Notice of Compliance on April 28, 2026 and launched the first generic semaglutide injection in Canada, the inaugural G7 approval for a generic version of the GLP‑1 drug. The product is offered in 2 mg and 4 mg...
ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Approved in the US for Two New Indications for Patients with HER2-Positive Early Breast Cancer
The FDA has approved AstraZeneca and Daiichi Sankyo’s ENHERTU (fam‑trastuzumab deruxtecan‑nxki) for both neoadjuvant and adjuvant treatment of HER2‑positive early‑stage breast cancer. In the neoadjuvant setting, ENHERTU plus taxane, trastuzumab and pertuzumab achieved a 67.3% pathologic complete response, outperforming standard...
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics received FDA clearance to begin the EXPRESS clinical trial of its UHeart xenotransplant, a pig‑derived heart with ten gene edits. The phase‑1/2/3 study will initially enroll up to two end‑stage heart‑failure patients, with safety and efficacy data reviewed...
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Agenus published Phase 1b data on botensilimab plus balstilimab in 19 patients with treatment‑refractory hepatocellular carcinoma who had progressed after prior immunotherapy. The combination achieved a 17% objective response rate, a 50% clinical benefit rate at 18 weeks, median progression‑free survival...
TRI-611
TRI‑611 is a CNS‑penetrant, CRBN‑mediated molecular‑glue degrader targeting ALK fusion proteins in ALK‑positive non‑small cell lung cancer (NSCLC). By recruiting a non‑G‑loop degron distal to the orthosteric site, it degrades ALK independently of the active site, sidestepping common tyrosine‑kinase inhibitor...
Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
The FDA has approved AstraZeneca’s Fasenra (benralizumab) for patients 12 and older with hypereosinophilic syndrome (HES), adding a rare‑disease indication to a drug already used for severe eosinophilic asthma. The approval rests on the Phase III Natron trial, which showed a...
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech...
Bristol Myers Squibb announced a $15.2 billion strategic licensing agreement with China’s Hengrui Pharma, front‑loading $600 million and targeting faster trial timelines. FDA Commissioner Marty Makary resigned, leaving acting head Kyle Diamantas—who lacks drug‑review experience—in charge and heightening regulatory uncertainty. Regenxbio reported clean...
As New Rules Take Hold, What Does ‘Good AI Practice’ Look Like in Drug Development?
On January 14 2026 the EMA and FDA published joint guiding principles that define good AI practice for drug development. The technology‑neutral framework emphasizes context of use, risk‑based controls, data governance, documentation and lifecycle management rather than adding new regulatory requirements. It...
World Clinical Trials Day 2026 Looks at the Science, Setbacks and Systems Behind New Medicines
World Clinical Trials Day 2026, observed on May 20, highlighted the “Research Rising” theme to honor the clinical‑research workforce and patients. Phase II studies now comprise 43% of the 584,000 active global trials, while oncology still drives 38% of Phase I‑III starts despite...
The FDA and a Breakthrough for Drug Repurposing Efforts
The FDA released a Request for Information (RFI) inviting submissions of FDA‑approved drugs that could be repurposed for unmet medical needs, especially in metabolic disease, neurodegeneration, gender‑specific health, substance‑use disorders, and rare diseases. The agency also seeks drug‑disease pairs with...
Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi
The FDA granted accelerated approval to BeOne Medicines' Beqalzi, the first BCL2 inhibitor for relapsed or refractory mantle‑cell lymphoma, after a Phase 1/2 trial showed a 52% overall response rate and median 15.8‑month durability. Taiho Oncology also received approval for Inqovi...
Transforming Clinical Trial Design and Avoiding AI Wrappers: Q&A with Angela Schwab
Trialynx CEO Angela Schwab explains how AI is reshaping clinical trial design by moving away from manual copy‑and‑paste protocols toward data‑driven, predictive modeling. AI can scan millions of past studies to suggest optimal endpoints, procedures, and patient pathways, reducing missed...
“Totally Unexpected” – Scientists Discover Pancreatic Cancer’s Fatal Addiction
Researchers at The Wistar Institute and ChristianaCare have uncovered a critical weakness in pancreatic cancer. They found that damaged mitochondria within tumor cells activate the TLR3‑TRAF6 signaling pathway, creating inflammation that the cancer depends on for growth. Blocking this pathway...
Investigating the Causes of Rheumatoid Arthritis Pain
Researchers at Karolinska Institutet used AMSBIO's adeno‑associated virus (AAV) vectors to conditionally knock out the Ifnar1 gene in sensory neurons of mouse models of rheumatoid arthritis (RA). By pharmacologically blocking the IFN1/MNK‑eIF4E signaling cascade, they achieved significant relief of joint...
Physical Fitness Does Not Strongly Influence Mainstream Epigenetic Clocks
Epigenetic clocks, built from DNA‑methylation patterns in blood, are widely used to estimate chronological age and mortality risk. A new systematic review and meta‑analysis of 44 studies involving 145,465 participants examined whether physical fitness influences these clocks. The analysis found...
The Case for Smarter Neuroinflammation Clinical Trials
INmune Bio, led by CEO David Moss, is developing non‑immunosuppressive therapies that target innate immune pathways, including the XPro1595 program for neurodegenerative disease and the CORDStrom mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa (RDEB). The company argues that...
Cell and Gene Therapy Catapult Invests in Lir Therapeutics to Accelerate Development of Its AI-Driven AAV Design Platform
The UK’s Cell and Gene Therapy Catapult is investing in Lir Therapeutics through Innovate UK’s Cross‑Catapult Investment Pilot to fast‑track Lir’s AI‑driven AAV capsid design platform, nAAVigator. The funding will support biological validation, benchmarking, and data generation to prove the platform’s...
Living ‘Tumour on a Chip’ Could Offer New Brain Cancer Insights
Researchers at Nottingham Trent University, in partnership with biotech firm Kirkstall Ltd, have built a living tumour‑on‑chip that mimics the human blood‑brain barrier to study glioblastoma. The microfluidic device cultivates patient‑derived brain‑cancer cells alongside a synthetic barrier, enabling real‑time monitoring...
The Biotech Bi-Weekly: Cell-Free Synthesis, in Situ Hybridization and Antibody Conjugation
The biotech bi‑weekly highlights three major product launches: Ribbon Bio introduced MiroSynth, a cell‑free DNA synthesis platform, and the MiroMine kit for in‑lab assembly; Empire Genomics and Molecular Instruments released NISH, the largest ready‑to‑use automated RNA in situ hybridization library; and Bio‑Rad...
AMX-883
Amphista Therapeutics announced AMX-883, an oral degrader that recruits the DCAF16 E3 ligase to eliminate the epigenetic reader BRD9. The preclinical program demonstrates selective BRD9 degradation in acute myeloid leukemia (AML) cell models, leveraging a previously identified BRD9 binder for...
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
Revvity, via its Immunodiagnostic Systems unit, secured FDA clearance for a Total Testosterone chemiluminescence immunoassay (ChLIA). The new assay joins FDA‑cleared free testosterone and SHBG tests, creating the only single‑platform, fully automated testosterone testing suite. The portfolio targets hypogonadism diagnosis...
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories and South Korean biotech MEDIPOST have signed a non‑exclusive memorandum of understanding to provide GMP‑compliant testing and regulatory support for MEDIPOST’s cell‑therapy pipeline. The collaboration will initially focus on the Asia‑Pacific and North American markets, with the...
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences announced the issuance of U.S. Patent No. 12,605,361 covering its carboxylated psilocybin‑derived EVM301 series for treating psychiatric disorders. The new patent expands the company’s intellectual‑property moat by protecting method claims that build on its earlier patent (No. 11,752,130). Enveric is...
Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing
Elpida Therapeutics and contract manufacturer Catalent have entered a strategic partnership to handle late‑phase manufacturing of Elpida’s lead AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Catalent will also receive exclusive rights to produce Elpida’s other adeno‑associated virus (AAV) programs,...
Putting the Boat Out at ASGCT26
Recent oncology‑focused CAR‑T developers are redirecting pipelines toward autoimmune diseases after compelling proof‑of‑concept data in refractory systemic lupus erythematosus and lupus nephritis. The shift includes both autologous and allogeneic cell products as well as emerging in‑vivo RNA‑based therapies delivered via...
Latest TechBio News
A wave of AI‑driven partnerships and funding rounds is reshaping drug discovery, from Insilico Medicine’s collaboration with Ribo on automated oligonucleotide research to LenioBio‑Twist’s 24‑hour cell‑free protein platform. AstraZeneca deepened its Immunai alliance, while Simulations Plus joined forces with NVIDIA...
What Success Can Look Like, Darn It
Vepdegestrant, marketed as Veppanu, became the first FDA‑approved bifunctional degrader, a new PROTAC‑type therapy that eliminates target proteins. A Phase III trial showed it works but delivered no clear efficacy advantage over the existing degrader fulvestrant. Pfizer and Arvinas have now...
Physionic Podcast Videos and Summaries / Transcripts
A 2023 meta‑analysis of 29,913 patients shows that pure EPA, administered as icosapent ethyl, significantly reduces myocardial infarction, cardiovascular death and all‑cause mortality. The REDUCE‑IT trial, using 4 g daily of prescription EPA, delivered a 25 % relative risk reduction and a...
Diabetes Reversed by Stem Cell-Derived Islets, Illustrating Promise for New Therapy
Researchers at Karolinska Institutet and KTH have devised a streamlined protocol that converts eight human pluripotent stem cell lines into highly pure, glucose‑responsive pancreatic islet cells. The cells produce insulin in vitro and, when transplanted into the eyes of diabetic...
Students Invented a New Diagnostic for Lyme Disease — and a Tool for CRISPR Researchers
Lambert High School’s 2025 iGEM team unveiled LANCET, a CRISPR‑Cas12a diagnostic that detects the Lyme‑causing bacterium’s CspZ protein up to 100 days after infection. The assay couples proximity‑dependent ligation of DNA aptamers with RPA amplification and a lateral‑flow readout, delivering...
Peek Behind the Paper | AxioParse: Streamlining Axiom Microbiome Assay Data Processing and Dataset Generation
AxioParse is a new computational framework that streamlines processing of data from Applied Biosystems’ Axiom Microbiome Array. The pipeline automates raw output parsing, quality‑control checks, and generation of analysis‑ready microbial profiles, reducing manual steps and variability. Developed by Mathieu Garand...
Trump Administration Blocks More Studies Showing Vaccines Healthy, Safe
During the Trump administration, the FDA suppressed three taxpayer‑funded studies that evaluated the safety of COVID‑19 and shingles vaccines. The research, which analyzed data from millions of patients, concluded that health benefits far exceeded the risk of serious adverse events,...
Novin AgriTech Secures USDA SBIR Grant to Develop Nitrogen Use Efficiency Trait in Elite Wheat Cultivars
Novin AgriTech secured a $174,906 USDA SBIR Phase I grant to fund an eight‑month project that will embed a nitrogen use efficiency (NUE) trait into elite wheat cultivars using its proprietary InPACT transformation platform. InPACT is a genotype‑independent, tissue‑culture‑free system licensed...
RESEARCH: TOCOTRIENOLS in COLORECTAL CANCER - 2024 Review Paper From Malaysia
A 2024 review from Malaysia examined 38 peer‑reviewed articles on tocotrienols, a subclass of vitamin E, and their effects on colorectal cancer. The analysis highlighted two isoforms, gamma‑ and delta‑tocotrienol, which consistently inhibited tumor cell proliferation, induced apoptosis, and reduced metastatic...
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
GlaxoSmithKline (GSK) has signed a 5.5‑year exclusive partnership with Chia Tai Tianqing Pharmaceutical Group to launch bepirovirsen, a chronic hepatitis B candidate, across more than 5,000 Chinese hospitals. The drug is currently in priority regulatory review in mainland China, while GSK...
Gene Therapy Is Giving Blind People Their Sight Back
Gene‑editing pioneers Katherine High, Jean Bennett and Albert Maguire won a Breakthrough Prize for Luxturna, the first FDA‑approved gene therapy that restores vision to people born with Leber congenital amaurosis. More than 100 blind Americans have already received the one‑time...